Cargando…

Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?

PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDING...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Howard (Jack), Barzi, Afsaneh, Wong, Debra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547555/
https://www.ncbi.nlm.nih.gov/pubmed/36208400
http://dx.doi.org/10.1007/s11912-022-01332-x
_version_ 1784805289063612416
author West, Howard (Jack)
Barzi, Afsaneh
Wong, Debra
author_facet West, Howard (Jack)
Barzi, Afsaneh
Wong, Debra
author_sort West, Howard (Jack)
collection PubMed
description PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDINGS: Research from a wide range of oncology facilities consistently demonstrates the feasibility of delivering telemedicine services over audio (telephone) and/or video platforms. Emerging work highlights that telemedicine is well suited for a subset of patients and clinical settings and that there are methods by which current disparities could potentially be ameliorated. Several current uncertainties limit the broad applicability of telemedicine longitudinally. SUMMARY: Early responses to the pandemic that included rapid introduction of telemedicine demonstrated the feasibility of audio- and video-based platforms that achieved promising utility, while simultaneously demonstrating disparities based on patient characteristics and infrastructural support. Its long-term role will likely depend greatly on reimbursement and regulatory reform.
format Online
Article
Text
id pubmed-9547555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95475552022-10-11 Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? West, Howard (Jack) Barzi, Afsaneh Wong, Debra Curr Oncol Rep Lung Cancer (H Borghaei, Section Editor) PURPOSE OF REVIEW: This paper summarizes early experiences of telemedicine during the COVID-19 pandemic, the patient and physician experience, limitations in accessibility introduced by telemedicine, and the opportunities and anticipated sustained role of telemedicine for cancer care. RECENT FINDINGS: Research from a wide range of oncology facilities consistently demonstrates the feasibility of delivering telemedicine services over audio (telephone) and/or video platforms. Emerging work highlights that telemedicine is well suited for a subset of patients and clinical settings and that there are methods by which current disparities could potentially be ameliorated. Several current uncertainties limit the broad applicability of telemedicine longitudinally. SUMMARY: Early responses to the pandemic that included rapid introduction of telemedicine demonstrated the feasibility of audio- and video-based platforms that achieved promising utility, while simultaneously demonstrating disparities based on patient characteristics and infrastructural support. Its long-term role will likely depend greatly on reimbursement and regulatory reform. Springer US 2022-10-08 2022 /pmc/articles/PMC9547555/ /pubmed/36208400 http://dx.doi.org/10.1007/s11912-022-01332-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Lung Cancer (H Borghaei, Section Editor)
West, Howard (Jack)
Barzi, Afsaneh
Wong, Debra
Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title_full Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title_fullStr Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title_full_unstemmed Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title_short Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?
title_sort telemedicine in cancer care beyond the covid-19 pandemic: oncology 2.0?
topic Lung Cancer (H Borghaei, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547555/
https://www.ncbi.nlm.nih.gov/pubmed/36208400
http://dx.doi.org/10.1007/s11912-022-01332-x
work_keys_str_mv AT westhowardjack telemedicineincancercarebeyondthecovid19pandemiconcology20
AT barziafsaneh telemedicineincancercarebeyondthecovid19pandemiconcology20
AT wongdebra telemedicineincancercarebeyondthecovid19pandemiconcology20